Salvage Surgery After Definitive Chemoradiotherapy for Non–small Cell Lung Cancer

Casiraghi, Monica; Maisonneuve, Patrick; Piperno, Gaia; Bellini, Roberto; Brambilla, Daniela; Petrella, Francesco; Marinis, Filippo de; Spaggiari, Lorenzo

doi:10.1053/j.semtcvs.2017.02.001

Cited by 61 publications

(74 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This issue can probably be explained by relatively less amount of mediastinal fibrosis due to the absence of concurrent CRT at the beginning, and the relatively low EQD2 (3Gy) of RT. The median OS after SS is 13-32.5 months in various series (3)(4)(5). Our case is disease-free at 83 months after SS without severe morbidity.…”

Section: Discussionmentioning

confidence: 59%

Long-Term Survival With Salvage Surgery in Persistent Lung Cancer

Er¹,

Kirli²,

Çetinayak³

et al. 2019

J Basic Clin Health Sci

View full text Add to dashboard Cite

Objective: Our study presents a case with locally-advanced non-small cell lung cancer (NSCLC) having salvage pneumonectomy due to persistent disease. Case Description: A 46-year old man with stage IIIB (cT4N3M0) NSCLC received 39Gy (13x3Gy) thoracic radiotherapy after neoadjuvant chemotherapy. Partial response was obtained after radiotherapy. Chemotherapy was continued after radiotherapy. At 28th month of followup without treatment, isolated local progression was detected. The patient underwent right pneumonectomy and mediastinal lymph node dissection revealing ypT2aN0 adenocarcinoma. After adjuvant chemotherapy, he's disease-free at 88 months after salvage surgery. Conclusion: In selected patients, salvage surgery seems to provide increased survival causing acceptable morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 59%

Long-Term Survival With Salvage Surgery in Persistent Lung Cancer

Er¹,

Kirli²,

Çetinayak³

et al. 2019

J Basic Clin Health Sci

View full text Add to dashboard Cite

show abstract

“…В отличие от неоадъювантной ХЛТ, когда оперативные вмешательства выполняют через 3-4 нед после ее окончания при отсутствии фиброзных изменений тканей средостения, «salvage»-операции технически сложны, поскольку хирурги вынуждены оперировать через несколько месяцев и даже лет после проведенной ХЛТ в условиях выраженного фиброза [2][3][4]. Не удивительно, что более 90,0% всех операций составляют пневмонэктомии с резекцией смежных органов и структур (перикард, мышечная стенка пищевода, предсердие) [5]. Нам удалось выполнить лобэктомию только у 1 больного.…”

Section: Discussionunclassified

“…Наибольшим опытом выполнения «salvage»операций при рецидиве РЛ обладают M. Casiraghi и соавт. [5], которые выполнили 43 подобных операции с летальностью 3,7%, 2-и 3-летней выживаемостью 51,0 и 42,0%, что соответствует полученным нами результатам: общая 3-летняя выживаемость -48,0%.…”

Section: Discussionunclassified

Surgery for non-small cell lung carcinoma after previous chemoradiotherapy alone

Пикин

Ryabov

Glushko

et al. 2016

Khir. Z. im. N.I. Pirogova

View full text Add to dashboard Cite

show abstract

“…Salvage surgery already plays a role in the treatment of esophageal cancer, colorectal cancer and other tumors . In recent years, salvage surgery has also been introduced into the treatment strategy of advanced lung cancer after chemotherapy/radiotherapy failure . In a study conducted by Hidetaka et al .…”

Section: Introductionmentioning

confidence: 99%

“…[15][16][17] In recent years, salvage surgery has also been introduced into the treatment strategy of advanced lung cancer after chemotherapy/radiotherapy failure. [18][19][20][21][22] In a study conducted by Hidetaka et al a complete pathological response was found in nearly half the cases who received salvage surgery after chemotherapy/radiotherapy. 23 However, the role of salvage surgery in patients with advanced lung cancer after targeted therapy has still not been well reported in the literature.…”

Section: Introductionmentioning

confidence: 99%

Salvage surgery for advanced non‐small cell lung cancer after targeted therapy: A case series

et al. 2020

View full text Add to dashboard Cite

Background Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non‐small cell lung cancer (NSCLC). There is a lack of high‐level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literature. Methods A retrospective analysis of patients who underwent salvage surgery in our center between January 2016 and June 2019 for advanced NSCLC after targeted therapy was performed. Results A total number of nine patients were identified, including five males and four females, with a median age of 56 years (range, 40–65 years), all diagnosed with lung adenocarcinoma stage IIIa–IVb. All patients had received targeted therapy according to individual positive mutation of driver gene(s). Salvage surgery was performed for tumor recurrence or residual tumor after a duration of 2–46 months of targeted therapy. A negative surgical margin was achieved in all cases. Postoperative complication rate was 11.1% (1/9). All patients were alive at the time of this analysis and two patients had disease progression. After a median follow‐up of 17 months (range: 5–44 months), the median event‐free survival and postoperative survival was 14 months (range: 2–44 months) and 17 months (range: 5–44 months) respectively. Conclusions Salvage surgery may be a feasible and promising therapeutic option for tumor recurrence or residual tumor in advanced NSCLC in selective patients after targeted therapy. Key points Salvage surgery is feasible in selected patients with advanced NSCLC and provides promising survival outcomes after targeted therapy failure. Salvage surgery provides precise molecular and pathological information which is most important for subsequent therapy.

show abstract

Salvage Surgery After Definitive Chemoradiotherapy for Non–small Cell Lung Cancer

Cited by 61 publications

References 19 publications

Long-Term Survival With Salvage Surgery in Persistent Lung Cancer

Long-Term Survival With Salvage Surgery in Persistent Lung Cancer

Surgery for non-small cell lung carcinoma after previous chemoradiotherapy alone

Salvage surgery for advanced non‐small cell lung cancer after targeted therapy: A case series

Contact Info

Product

Resources

About